BG
CGON icon

Bellevue Group’s CG Oncology CGON Stock Holding History

Bellevue Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1M Buy
+493,596
New +$32.3M 0.74% 37
2026
Q1 		– Sell
-3,095
Closed -$129K – 165
2025
Q4 		$129K Buy
+3,095
New +$128K ﹤0.01% 158

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group's CGON Position: Q2 2026 in Review

Bellevue Group opened a new position in CG Oncology (CGON) in Q2 2026: 493,596 shares worth $35.1M. The stake represents 0.74% of the portfolio and ranks #37 among its holdings. This is a return to the name: Bellevue Group previously reported a position in CGON as recently as Q4 2025.

Bellevue Group first reported a position in CGON in Q4 2025 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Bellevue Group held 493,596 shares of CG Oncology worth $35.1M as of Q2 2026.
  • CG Oncology was a new Bellevue Group position in Q2 2026.
  • CG Oncology made up 0.74% of Bellevue Group's portfolio in Q2 2026, its #37 holding.
  • Bellevue Group first reported a position in CG Oncology in Q4 2025 and has held it in 2 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.